Fig. 3: Cumulative incidence of CEs over time, according to number of cardiac risk factors. | British Journal of Cancer

Fig. 3: Cumulative incidence of CEs over time, according to number of cardiac risk factors.

From: Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

Fig. 3

At 6, 12 and 18 months from randomisation, patients with 0–1 risk factors have an incidence of CE of 1.3%, 2.1% and 2.1%, respectively. Patients with 2–3 risk factors, at the same time-points, have an incidence of CE of 4.5%, 7.2% and 7.7%, respectively. For those with 4 risk factors, the incidences are 9.2%, 14.0% and 14.0%, respectively. Note that any given patient could have accumulated up to 4 risk factors, instead of the 5 identified, since none was exposed both to doxorubicin and epirubicin.

Back to article page